



## FORMULATION ASPECTS IN THE DEVELOPMENT OF ORODISPERSIBLE TABLETS: AN OVERVIEW

TAPAN KUMAR GIRI<sup>1\*</sup>, DULAL KRISHNA TRIPATHI<sup>1</sup> AND RANA MAJUMDAR<sup>2</sup>

<sup>1</sup>Rungta College of Pharmaceutical Sciences & Research, Kohka Road, Kurud, Bhilai-491024, India, <sup>2</sup>Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences, Uluberia, Howrah-711316, India Email: tapan\_ju01@rediffmail.com

Received: 26 April 2010, Revised and Accepted: 07 May 2010

### ABSTRACT

Over the past three decades, orodispersible tablets (ODTs) have gained considerable attention as a preferred alternative to conventional tablets and capsules due to better patient compliance. Upon introduction into the mouth, these tablets dissolve or disperse in the mouth in the absence of additional water and the active pharmaceutical ingredients are readily released from the dosage form. These tablets are convenient for young children, elderly and patients with swallowing difficulties, and in situations where a potable liquid (water) is not available. Products of ODT technologies entered the market in the 1980s and have grown steadily in demand. Their product pipelines are rapidly expanding. The popularity and usefulness of these formulations resulted in development of several ODT technologies. In the present review the formulation techniques and different technologies are discussed.

**Keywords:** Orodispersible tablets, disintegration time, superdisintegrant, direct compression

### INTRODUCTION

In recent years, considerable attention has been focused on the development of novel drug delivery systems (NDDS). The reason for this paradigm shift may be due to relatively low development cost and time required for introducing a NDDS (\$ 20-50 million and 3-4 years respectively) as compared to a new chemical entity (approximately \$ 500 million and 10-12 years, respectively). In the form of NDDS, an existing drug molecule can get a 'new life', thereby increasing its market value, competitiveness, and patent life.

Among the various NDDS available in market, orodispersible tablets hold the major share because of their obvious advantages of ease of administration and better patient compliance. Difficulty in swallowing a tablet or capsule is a common problem of all age groups, especially of elderly and paediatrics, because of physiological changes associated with these groups of patients. Other categories of patients that experience problems in using conventional oral dosage forms includes the mentally ill, uncooperative, nauseated patients, and those with conditions of motion sickness, sudden episodes of allergic attack or coughing. Sometimes, it may be inconvenient to swallow a conventional product due to unavailability of water. These problems led to the development of novel type of solid oral dosage form called "orodispersible tablet".

ODTs are known by various names such as mouth dissolving, fast dissolving, fast melting, rapidly disintegrating, orally disintegrating tablets. The European pharmacopoeia defines the term "orodisperse" as a tablet that can be placed in the mouth where it disperses rapidly before swallowing<sup>1</sup>. Suitable drug candidates for such systems include neuroleptics, cardiovascular agents, analgesics, anti-allergics and drugs for erectile dysfunction<sup>2</sup>. Such a tablet disintegrates instantaneously when placed on tongue, releases the drug that dissolves or disperses in the saliva. As the oral mucosa is highly vascularised<sup>3</sup>, drugs that are absorbed through the oral mucosa can directly enter into the systemic circulation, bypassing the gastrointestinal tract (GIT) and therefore first-pass metabolism in the liver. This results to a rapid onset of action<sup>4</sup>, and greater bioavailability of the drug than those observed from conventional tablet dosage form<sup>5</sup>.

During the last decade, several new advanced technologies have been introduced for the formulation of ODTs with very interesting features, like extremely low disintegration time, exceptional taste masking ability, pleasant mouth feel and sugar free tablets for diabetic patients. Various technologies utilized for fabrication of ODTs and these techniques are based on the principles of increasing

porosity by addition of superdisintegrants and/or water soluble excipients in the tablets.

### Advantages of ODTs

ODTs have the advantages of ease of administration to the patient who cannot swallow, such as the elderly, stroke victims, bedridden patients, patient affected by renal failure and patient who refuse to swallow such as paediatric, geriatric and psychiatric patients. No need of water to swallow the dosage form, which is highly convenient for patients who are travelling and do not have immediate access of water. From the pharmaceutical industry's point of view, ODTs can provide new dosage forms as a life cycle management tool for drugs near the end of their patent life.

Because, the tablets disintegrate inside the mouth, drugs may be absorbed from the pregastric area i.e., mouth, pharynx and oesophagus which may produce rapid onset of action<sup>6,7</sup>, prevent loss of drug due to first-pass effect. Pre-gastric absorption can result in improved bioavailability, reduced dose and improved clinical performance by reducing side effects<sup>8</sup>.

### Characteristics and formulation challenges of ODTs

The key properties of the tablets are fast absorption or wetting of water into the tablets and disintegration of associated particles into individual components for fast dissolution. This requires that excipients should have high wettability, and the tablet structure should also have a highly porous network. Because the strength of a tablet is related to compression pressure, and porosity is inversely related to compression pressure, it is important to find the porosity that allows water absorption faster with maintenance of higher mechanical strength. ODTs should have low sensitivity to moisture for greater stability. A good package design or other strategy should be created to prevent ODTs from various environmental conditions<sup>2</sup>.

For the ideal ODTs technology, the drug properties should not significantly affect the tablet property for example; the solubility, crystal morphology, particle size, hygroscopicity, compressibility, and bulk density of a drug can significantly affect the final characteristics of tablets, such as porosity, tablet strength, disintegration and dissolution.

As the ODTs dissolve or disintegrate in the patient's mouth, the drug will be partially dissolved in close proximity to the taste buds. Thus, the taste inside the mouth becomes critical for patient acceptance. When the drug is tasteless or does not have an undesirable taste, taste masking techniques does not become so important. The taste-masking technology should not affect the ODT formulation. There are various ODTs tablets available in the market (Table 1).

Table 1: Commercially available ODT products

Trade name	Active ingredient	Manufacturer
Dolib MD	Rofecoxib	Panacea
Rofaday MT	Rofecoxib	Lupin
Orthoref MD	Rofecoxib	Biochem
Torrox Mt	Rofecoxib	Torrent
Benadryl Fast melt	Diphenhydramine	Warner Lambert
Kemstro	Baclofen	Schwarz Pharma
Imodium instant melts	Loperamide HCl	Janssen
Mosid MT	Mosapride	Torrent
Domray MD	Domperidone	Ray Remedies
Values	Valdecoxib	Glenmark
Nimulid MD	Nimusulide	Panacea
Zotacet MD	Cetirizine HCl	Zota Pharma
Romilast	Montelukast	Ranbaxy
Olanex Instab	Olanzapine	Ranbaxy
Maxalt-MLT	Rizatriptan Benzoate	Merck
Febrectol	Paracetamol	Prographarm
Pepcid ODT	Famotidine	Merck
Zyprexa	Olanzapine	Eli Lilly
Zofran ODT	Ondansetron	GSK
Klonopin Wafers	Clonaxepam	Roche
Zoming ZMT	Zolmitriptan	Astra Zeneca
Cibalginadue FAST	Ibuprofen	Novartis Consumer Health
Nulev	Hyocyanine sulphate	Schwarz Pharma
Benadryl Fastmelt	Diphenhydramine	Pfizer
Feldene melt	Piroxicam	Pfizer
Tempra Quicklets	Acetaminophen	Bristol Myers Squibb
Kid Relief	Acetaminophen	Ethypharm
Claritin Reditabs	Loratidine	Schering-Plough
Zelapar TM	Selegiline	Amarin Corp
Risperdal	Risperidone	Janssen Pharmaceutica Products

### Techniques for preparing ODTs

The various techniques are being utilized or adopted to prepare ODTs

- a) Direct Compression
- b) Sublimation
- c) Humidity treatment
- d) Sintering
- e) Wet Granulation
- f) Dry Granulation
- g) Melt Granulation
- h) Spray Drying
- i) Moulding
- j) Freeze Drying

#### a) Direct compression

Conventional equipment, commonly available excipients and a limited number of processing steps are involved in direct compression. This technique can now be applied for preparation of ODT, because of the availability of improved excipients especially super disintegrants and sugar based excipients.

The introduction of superdisintegrants has increased the popularity of this technology<sup>9</sup>. Below a critical level of disintegrant concentration, tablet disintegration time becomes inversely proportional to disintegrant concentration.

However, above the critical concentration level of disintegrant, disintegration time remains approximately constant or the decrease is insignificant<sup>10</sup>. Bi et al.<sup>11</sup> and Watnabe<sup>12</sup> used microcrystalline cellulose (MCC) and low substituted hydroxypropyl cellulose (HPC) to manufacture ODTs wherein the ratio of MCC to HPC varied from 8:2 to 9:1. Another approach to manufacture ODTs by direct compression is the use of sugar-based excipients (dextrose, fructose, isomalt, maltose, mannitol, sorbitol, xylitol) which display high aqueous solubility and sweetness and hence, imparts taste masking and a pleasing mouth feel.

#### b) Sublimation

The presence of highly porous structure in the tablet is the key factor for rapid disintegration of ODT. When volatile materials are compressed into tablets using the conventional method, they can be removed via sublimation, resulting in highly porous structures. The volatile materials include urea, ammonium carbonate, ammonium bicarbonate, hexa methylene tetramine, and camphor. Heinemann<sup>13</sup> disclosed a process to prepare porous tablets by sublimation. The mixtures of volatile adjuvants were made into tablets and subsequently heated. The volatile ingredient while leaving the core of tablet makes pores into it.

#### c) Humidity treatment

The mechanical strength of some tablets increased substantially after moisture treatment, compared with the tablets before the treatment. The increase is known to be due to the formation of liquid bridges in the presence of moisture and then formation of solid bridges after drying. When an amorphous sugar is treated to go through the humidification and drying process, it changes to a crystalline state. This change increases the tablet strength substantially<sup>14,15</sup>.

In a patent by Mizumoto et al<sup>15</sup> a drug, a sugar, and an amorphous sugar capable of transforming from amorphous to crystalline state were mixed and compressed into tablets. After the tablets were formed, they were humidified and dried. The "amorphous sugar" are those that can form an amorphous state by spray drying, freeze drying, or other granulation methods. These amorphous sugars include glucose, lactose, maltose, sorbitol, trehalose, lactitol, and fructose. The relative humidity is determined by the apparent critical relative humidity of the mixture of a drug and an amorphous sugar. A relative humidity greater than or equal to the critical relative humidity of this mixture is chosen for the humidity condition. The advantage of using amorphous sugar is that they have low critical relative humidity, so that they can absorb water even at low moisture levels. If a high humidity condition is used, tablets may adhere together, causing manufacturing problems. Another advantage of using amorphous sugar is that transformation of the

amorphous state to the crystalline state is irreversible. The sugars in crystalline state have a high critical moisture point, so the strengthened tablets are less susceptible to moisture.

#### d) Sintering

When thermal energy is applied to a powder compact, the compact is densified and the average grain size increases. The basic phenomena occurring during this process, called sintering, are densification and grain growth. Lagoviyer et al<sup>16</sup> disclosed a process that tablet strength can be increased by sintering the tablet components at high temperatures and then resolidifying them at lower temperatures. The components in this formulation include bulk agents, structure agents, solvent, and binding agents. A bulk agent in this formulation is used to provide bulk volume to the overall tablet, and suitable agents include carbohydrates, calcium carbonate, and magnesium carbonate. The suitable structure agents should provide a porous support structure to allow quick dissolution of the tablets in the mouth. Solvents can be chosen from water, ethyl alcohol, isopropyl alcohol, or a mixture thereof. Binders are water soluble polymers such as polyethylene glycol (PEG), with a molecular weight of approximately 1000 to 1,000,000. All the ingredients dissolved into solvent and spray dried into granules. The granules are then lightly compressed to form tablets. These tablets are heated for a sufficient time and temperature to allow the binding agent to melt. The heating step is intended to melt the binding agent to create intra-tablet bonds and help weld the product shape together. Typically, a laboratory oven is set at around 50-100°C. The heating time ranges from 3 to 45 minutes. The binding agents are resolidified as the temperature is reduced to ambient temperature. The disintegration time is generally within 3-60 seconds.

#### e) Wet granulation

Bonadeo et al<sup>17</sup> described a process of producing ODTs by wet granulation in a fluidized bed. The formulation includes polyalcohols (e.g., mannitol, xylitol, sorbitol, maltitol, erythritol, and lactitol), 1-30% of an edible acid, and an active ingredient as the dry mixture. This mixture was wet granulated with an aqueous solution of a water-soluble or water-dispersible polymer (e.g. polyethylene glycols, carrageenan, and ethyl cellulose), which consisted of 1-10% of the final weight of the granule in a fluid bed. Granules with high porosity and low apparent density were obtained, and the tablets made by such granules had rapid disintegration times ranging from 3 to 30 seconds in the saliva.

#### f) Dry Granulation

Eoga and Valia<sup>18</sup> disclosed a method of preparation of ODTs by dry granulation. Low-density alkali earth metal salts or water-soluble carbohydrates were precompact, and the resulting granules were compressed into tablets that could dissolve fast. In this process, a powdered material with a density of 0.2 to 0.55 gm/ml was precompact to increase the density to 0.4 to 0.75 g/ml by applying pressure ranging from 1 to 9 kN/cm. The resulting granules were compressed into tablets.

#### g) Melt granulation

Abdelbery et al<sup>19</sup> described a new approach of preparing ODTs with sufficient mechanical strength, involving the use of a hydrophilic waxy binder (Superpolystate<sup>®</sup>, PEG-6-stearate) by melt granulation or wet granulation. In case of melt granulation granules were prepared in a high speed blade mixer at 40-44°C, according to the conventional hot-melt procedure. For wet granulation, an oil-in-water emulsion of Superpolystate<sup>®</sup> was used as the granulating agent. Then, granules were blended with croscarmellose, aspartame, and magnesium stearate and compressed into tablets. The melt granulation ODTs had better hardness results than the wet granulation ODTs. The disintegration times of melt granulation tablets, however, was more than one minutes.

#### h) Spray drying

Spray drying technique produces highly porous and fine powders as the processing solvent is evaporated during this process. Allen et al<sup>20</sup> have used spray-drying for the production of ODTs. The formulations contained hydrolyzed and nonhydrolyzed gelatine

(same net charge) as a supporting agent for the matrix, mannitol as a bulking agent and sodium starch glycolate/croscarmellose as a disintegrant.

To maintain the net charges of the gelatine, an acidifying or alkalizing agent was included. The reason to use gelatine components of the same charge was that molecules would repel each other even after spray drying, so that the porous particles could be formed. A minimal amount of an effervescent agent was optimally included to further accelerate the dissolution rate. The suspension of above excipients was spray-dried to yield a porous powder which was compressed into tablets. Tablets manufactured by this method disintegrated in less than 20 seconds in aqueous medium.

#### i) Moulding

Moulded tablets contain water soluble ingredients due to which the tablets dissolve completely and rapidly. Moulding process is of two type's i.e. solvent method and heat method. Solvent method involves moistening the powder blend with a hydroalcoholic solvent followed by compression at low pressure in moulded plates to form a wetted mass. The solvent is then removed by air drying. The heat moulding process involves preparation of a suspension that contains a drug, agar and sugar (e.g. mannitol or lactose) and pouring the suspension in the blister packaging wells, solidifying the agar at the room temperature to form a jelly and drying at 30°C under vacuum. Pebley et al<sup>21</sup> evaporated the frozen mixture containing a gum (e.g. acacia, carageenam, guar, tragacanth or xanthan), a carbohydrate (e.g. dextrose, lactose, maltose, mannitol or maltodextrin) and solvent in a tablet-shaped mould to design a ODT with a disintegration time of about 20-60 seconds.

#### j) Freeze drying

In freeze drying process, the water is sublimed from the product after it is frozen. The active drug is dissolved or dispersed in an aqueous solution of a carrier/polymer. The mixture is poured in the walls of the preformed blister packs. The trays holding the blister packs are passed through liquid nitrogen freezing tunnel to freeze the drug solution or dispersion. Then the frozen blister packs are placed in refrigerated cabinets to continue the freeze drying. After freeze drying the aluminium foil backing is applied on a blister sealing machine. Jaccend and Leyder<sup>8</sup> used freeze drying to develop an oral formulation of several drugs such as spiranolactone and trolendomycin. Corveleyn and Remon<sup>5,22</sup> studied various formulations and process parameters by using hydrochlorothiazide as a model drug.

### PATENTED TECHNOLOGIES FOR ODTs

#### Zydis technology

Zydis is a unique freeze dried oral solid dosage form that can be administered without water and it dissolves instantly on the tongue in less than 3 seconds.

The drug is physically trapped in a water soluble matrix, and then freeze dried to produce a product that rapidly dissolves. The matrix usually contain excipients like polymers (e.g., gelatine, alginates, and dextrin) to provide strength and rigidity to tablets; polysaccharides (e.g., mannitol and sorbitol) to impart crystallinity and hardness to the matrix and to improve palatability; collapse protectants (e.g, glycin) to prevent the product from shrinking in its packaging during manufacturing or storage; flocculating agents (e.g, xanthan gum and acacia) to provide uniform dispersion of drug particles; preservatives (e.g., parabens) to prevent microbial growth; permeation enhancers (e.g., sodium lauryl sulphate) to improve transmucosal permeability; pH adjusters (e.g, citric acid) to optimize chemical stability; flavours and sweeteners to improve patient compliance and water to ensure formation of porous units.

Thirteen products are currently available based on zydis technology<sup>23</sup>. In US, the zydis products available are Claritin Reditab, Dimetapp Quick Dissolve, Feldene Melt, Maxalt-MLT, Pepcid RPD, Zofran ODT, and Zyprexa Zydis. In the worldwide market, zydis formulations are also available for oxazepam, lorazepam, loperamide, and enalapril<sup>24</sup>.

### Orasolv technology

CIMA labs have developed orasolv technology<sup>25</sup>. It uses an effervescent agent that releases gas upon contact with water. Effervescent agent usually includes an acid source and a carbonate source. The acid sources include citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, and succinic acids. The carbonate sources include sodium bicarbonate, sodium carbonate, potassium bicarbonate, and potassium carbonate. Tablets are prepared by direct compression at low compression force in order to minimize oral disintegration time. The active medicaments are taste masked and dispersed in saliva due to the action of effervescent agents. It provides the pleasant sensation in mouth of the patient.

### Durasolv technology

Durasolv<sup>26</sup> is the patented technology of CIMA labs. The tablets made by this technology consist of a drug, fillers and a lubricant. Tablets are prepared by direct compression technique using conventional tableting equipment and have good rigidity. These can be packed into conventional packaging systems like blisters. Durasolv is an appropriate technology for products requiring low amounts of active ingredients.

### Wowtab technology

Wowtab technology<sup>27</sup> is patented by Yamanouchi pharmaceutical company. Wow means "without water". In this process, combination of low mouldability saccharides and high mouldability saccharides are used to obtain a rapidly melting strong tablet. Various low-mouldability saccharides are lactose, mannitol, glucose, sucrose and xylitol. Also various high-mouldability saccharides are maltose, maltitol, and sorbitol. A tablet prepared with low-mouldability or high-mouldability saccharides alone does not achieve adequate hardness and quick disintegration simultaneously. However if both the saccharides physically mixed before compression quick disintegration cannot be obtained. For this reason the active ingredient is mixed with a low-mouldability saccharide and granulated with a high-mouldability saccharide and compressed into tablet.

### Flashtab technology

Flashtab technology<sup>28</sup> is patented by Prographarm laboratories. Tablets prepared by this system consist of an active ingredient in the form of microcrystals. Drug micro-granules may be prepared by using the conventional techniques like coacervation, microencapsulation, and extrusion-spheronization. All these processes utilized conventional tableting technology.

### Pharmaburst technology

Pharmaburst technology is patented by SPI pharma. Tablet manufactured by this process involves a dry blend of a drug, flavour, and lubricant followed by compression into tablets; which dissolve within 30-40 seconds. Tablets manufactured by this method having sufficient strength so they can be packed in blister packs and bottles<sup>29</sup>.

### Shearform technology

The shearform technology<sup>27,28</sup> is based on preparation of floss that is also known as 'shearform matrix', which is produced by subjecting a feed stock containing a sugar carrier by flash heat processing. The tablets manufactured by this process are highly porous in nature and offer very pleasant mouth feel due to rapid solubilisation of sugars in presence of saliva. At first sucrose in combination with mannitol/dextrose and surfactant is blended to form the floss mix. The surfactant acts as a crystallization enhancer in maintaining the structural integrity of the floss fibres and also helps in the conversion of amorphous sugar into crystalline form from an outer portion of amorphous sugar mass. Subsequently in the flash heat process, the heat induces an internal flow condition of the carrier material. This is followed by its exit through the spinning head that flings the floss under centrifugal force and draws into long and thin floss fibres, which are usually amorphous in nature. The floss so produced is further chopped (conversion of fibres into smaller particles in a high shear mixer granulator) and recrystallized

through an ethanol treatment(1%) which is sprayed onto the floss and subsequently evaporated to impart improved flow and cohesive properties to the floss. The recrystallized matrix is then blended with the drug along with other excipients and compressed into tablets. In order to improve the mechanical strength the tablets are exposed to elevated temperature and high humidity (40°C and 85% RH for 15 minutes).

### Ceform Technology

In ceform technology<sup>29</sup> microspheres containing active drug ingredient are prepared. The essence of ceform microsphere manufacturing process involves placing a dry powder, containing pure drug and excipients into a rapidly spinning machine. The centrifugal force of the rotating head of ceform machine throws the dry drug blend at high speed through small heated openings. The carefully controlled temperature of the resultant microburst of heat liquefies the drug blend to form a sphere without adversely affecting drug stability. The microspheres are then blended and/or compressed into the preselected oral dosage format.

### Ziplet Technology

In ziplet technology water insoluble drugs or drugs as coated microparticles are used. The addition of a suitable amount of a water-insoluble inorganic excipients combined with disintegrants imparted an excellent physical resistance to the ODT and simultaneously maintained optimal disintegration<sup>30</sup>. The use of water-insoluble inorganic excipients offer better enhancement of disintegration in comparison to the most commonly used water-soluble sugars or salts. Tablets primarily of water soluble components often tend to dissolve rather than disintegrate and concentrated viscous solution is formed which reduces the rate of water diffusion into the tablet core<sup>9</sup>.

### Oraqquick technology

Oraqquick is a patented taste masking technology pioneered by KV pharmaceuticals. It supports the incorporation of taste masking technology. The taste masking process does not utilize solvents of any kind and therefore leads to faster and efficient production. Tablets with sufficient mechanical strength without disrupting taste masking are obtained after compression. This technology had also been utilized in the development of ODTs containing hyoscyamine sulphate which is a bitter tasting drug<sup>31</sup>.

### Frosta Technology

This technology is patented by Akina. Frosta technology utilizes the core concept of formulating plastic granules and compressing at low pressure to produce strong tablets with high porosity. The process involves mixing the porous plastic material with water penetration enhancer and followed by granulating with binder. The technology can be used for almost any drugs including aspirin, loratidine, caffeine, and folic acid, vitamins and dietary supplements. Melting time varies from several seconds to about 10 seconds depending on the formulation.

### Nanocrystal technology

Nanocrystal technology is patented by Elan, King of Prussia. Nanocrystal ODT technology provides for pharmacokinetic benefits of orally administered nanoparticles (less than 2 microns) in the form of a rapidly disintegrating tablet matrix. Nanocrystal technology includes lyophilisation of colloidal dispersions of drug substances and water soluble ingredients filled into blister pockets. This method avoids manufacturing process such as granulation, blending and tableting which is more advantageous for highly potent hazardous drug.

### CONCLUSION

The techniques and technologies described in this article represent how recent advances in formulation development and processing technologies make the efforts to achieve orodispersible tablets. ODTs have better patient acceptance and compliance and may offer improved biopharmaceutical properties, improved efficacy, and

better safety compared with conventional oral dosage forms. To provide the patients with the most conventional mode of administration, there was a need to develop rapidly disintegrating dosage form, particularly one that disintegrates and dissolve/disperse in saliva and can be administered without need of water. A number of ODT products based on various technologies are now commercially available in the international market. The basic approach followed by all the available ODTs technologies is to maximize the porous structure of tablet matrix to achieve rapid tablet disintegration in the oral cavity along with good taste-masking properties and excellent mechanical strength.

#### REFERENCES

- European pharmacopoeia, 4<sup>th</sup> Edition, Supplement 4.2; 2002. p2435.
- Chang RK, Guo X, Burnside BA, Couch RA. Fast dissolving tablets. *Pharm .Technol.* 2000; 24:52-58.
- Hoogstrate AJ, Verhoef JC, Tuk B, Pijpers A. In-vivo buccal delivery of fluorescein isothiocyanate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pig. *J. Pharm .Sci.* 1996;85:457-460.
- Keiko T, Yasuko O, Tsuneji N, Thorseinn L, Kozo T. Buccal absorption of ergotamine tartrate using the bioadhesive tablet system in guinea-pigs. *Int. J .Pharm.* 2002;238:161-170.
- Corveleyn S, Remon JP. Formulation and production of rapid disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug. *Int. J .Pharm.* 1997;152:215-225.
- Fix JA. Advances in quick-dissolving tablets technology employing Wowtab. Paper presented at: IIR Conference of drug delivery systems. 1998 Oct.; Washington DC, USA.
- Virely P, Yarwood R. Zydis-a novel, fast dissolving dosage form. *Manuf. Chem.* 1990; 61: 36-37.
- Jaccard TT, Leyder J. Une nouvelle forme galenique: le lyoc, [ A new galenic form: lyoc] *Ann. Pharm .Fr.* 1985; 43: 123-131.
- Shangraw R, Mitrevej A, Shah M. A new era of tablet disintegrants. *Pharm. Technol.* 1980; 4: 49-57.
- Ringard J, Guyot-Hermann AM. Calculation of disintegrant critical concentration in order to optimize tablet disintegration. *Drug. Dev. Ind. Pharm.* 1988; 14: 2321-2339.
- Bi Y, Sunada K, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. *Chem. Pharm. Bull.* 1996; 44: 2121-2127.
- Watanabe Y. New compressed tablet rapidly disintegrating in the mouth using crystalline cellulose and a disintegrant. *Biol. Pharm. Bull.* 1995; 18: 1308-1310.
- Heinemann H, Rothe W. Preparation of porous tablets. *US Patent* 3, 885, 026;1975.
- Sugimoto M, Matsubara K, Koida Y, Kobayashi M. The preparation of rapidly disintegrating tablets in the mouth. *Pharm.Dev .Technol.* 2001; 6(4): 487-493.
- Mizumoto T, Masuda Y, Kajiyama A, Yanagisawa M, Nyshadham JR. Tablets quickly disintegrating in the oral cavity and process for producing the same. *US patent* 6, 589,554; 2003.
- Lagoviyer Y, Levinson RS, Stotler D, Riley TC. Means for creating a mass having structural integrity. *US patent* 6, 465,010;2002.
- Bonadeo D, Ciccarello F, Pagano A. Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained by thereby. *US Patent* 6, 149, 938; 1998.
- Eoga AB, Valia KH. Method for making fast melt tablets. *US Patent* 5,939,091; 1999.
- Abdelbery G, Prinderre P, Eouani C, Joachim J, Reynier JP, Piccerelle P. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. *Int. J .Pharm.* 2004; 278(2): 423-433.
- Allen LV, Wang B, Davis JD. Rapidly dissolving tablet. *US patent* 5, 807, 576; 1998.
- Pebley WS, Jager NE, Thompson SJ. Rapidly disintegrating tablet. *US Patent* 5, 298, 261; 1994.
- Corveleyn S, Remon JP. Freeze-dried disintegrating tablets. *US patent* 6, 010, 719; 2000.
- Allen Loyd V. Flavors and flavouring. *Int. J .Pharm .Compounding.* 1997; 1: 90-92.
- Devrajan PV, Gore SP. Melt-in-mouth tablets: innovative oral drug delivery system. *Express .Pharm. Pulse.* 2000; 7: 16-26.
- Desai SA, Ferade SV, Petkar KC, Kuchkar DS. Orodisolving tablets of promethazine hydrochloride. *Ind. J. Pharm .Edu. Res.* 2006; 40(3): 172-174.
- Gohel M, Patel M, Amin A, Agarwal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. *AAPS Pharm .Sci .Tech.* 2004; 5(3):1-6.
- Yarwood RJ, Burruano B, Richard D, Hoy Michael R. Method for producing water dispersible sterol formulations. *US Patent* 5, 738, 875; 1998.
- Mizumoto T, Allen A, Loyd V. Method for producing a rapidly dissolving dosage form. *US Patent* 5, 576, 014; 1996.
- Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. *Crit. Rev. Ther .Drug. Carrier. Sys.* 2004; 21: 433-476.
- Debetti L. Fast disintegrating tablets. *PCT Patent* WO 99/44580-A1; 1999.
- Pharmabiz. KV Pharmaceutical launches first product utilizing proprietary Ora Quick delivery system. 2003. <http://www.pharmabiz.com/article/detnews.asp? Arch = &articleid=13837&sectioned=14>.